Pub. Date : 2004 Dec
PMID : 15596048
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 2 | ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 3 | In addition, ZD6474 showed dose-dependent inhibition of EGFR phosphorylation in PC-9 cells, but inhibition was only partial in PC-9/ZD cells. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 4 | ZD6474-mediated inhibition of tyrosine residue phosphorylation (Tyr992 and Tyr1045) on EGFR was greater in PC-9 cells than in PC-9/ZD cells. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 5 | These findings suggest that the inhibition of EGFR phosphorylation by ZD6474 can contribute a significant, direct growth-inhibitory effect in tumor cell lines dependent on EGFR signaling for growth and/or survival. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 6 | These findings suggest that the inhibition of EGFR phosphorylation by ZD6474 can contribute a significant, direct growth-inhibitory effect in tumor cell lines dependent on EGFR signaling for growth and/or survival. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 7 | These studies demonstrate that the additional EGFR TKI activity may contribute significantly to the antitumor efficacy of ZD6474, in particular in those tumors that are dependent on continued EGFR-signaling for proliferation or survival. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 8 | These studies demonstrate that the additional EGFR TKI activity may contribute significantly to the antitumor efficacy of ZD6474, in particular in those tumors that are dependent on continued EGFR-signaling for proliferation or survival. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 9 | In addition, these results provide a preclinical rationale for further investigation of ZD6474 as a potential treatment option for both EGFR-TKI-sensitive and EGFR-TKI-resistant tumors. | vandetanib | epidermal growth factor receptor | Homo sapiens |
| 10 | In addition, these results provide a preclinical rationale for further investigation of ZD6474 as a potential treatment option for both EGFR-TKI-sensitive and EGFR-TKI-resistant tumors. | vandetanib | epidermal growth factor receptor | Homo sapiens |